Digoxin toxicity

Last updated
Digoxin toxicity
Other namesDigoxin poisoning, digoxin overdose
Digitalis purpurea Koehler drawing.jpg
Drawings of Digitalis purpurea
Specialty Emergency medicine
Symptoms vomiting, loss of appetite, confusion, blurred vision, changes in color perception, decreased energy [1]
Complications Heart dysrhythmia [1]
CausesExcessive digoxin, plants such as foxglove [1] [2]
Risk factors Low potassium, low magnesium, high calcium [1]
Differential diagnosis Acute coronary syndrome, hyperkalemia, hypothyroidism, beta blocker toxicity [2]
Treatment Supportive care, activated charcoal, atropine, digoxin-specific antibody fragments [2] [1]
Frequency~2,500 cases per year (US) [2]

Digoxin toxicity, also known as digoxin poisoning, is a type of poisoning that occurs in people who take too much of the medication digoxin or eat plants such as foxglove that contain a similar substance. [1] [2] Symptoms are typically vague. [1] They may include vomiting, loss of appetite, confusion, blurred vision, changes in color perception, and decreased energy. [1] Potential complications include an irregular heartbeat, which can be either too fast or too slow. [1]

Contents

Toxicity may occur over a short period of time following an overdose or gradually during long-term treatment. [1] Risk factors include low potassium, low magnesium, and high calcium. [1] Digoxin is a medication used for heart failure or atrial fibrillation. [3] An electrocardiogram is a routine part of diagnosis. [2] Blood levels are only useful more than six hours following the last dose. [1]

Activated charcoal may be used if it can be given within two hours of the person taking the medication. [1] Atropine may be used if the heart rate is slow while magnesium sulfate may be used in those with premature ventricular contractions. [2] Treatment of severe toxicity is with digoxin-specific antibody fragments. [1] Its use is recommended in those who have a serious dysrhythmia, are in cardiac arrest, or have a potassium of greater than 5 mmol/L. [1] Low blood potassium or magnesium should also be corrected. [1] Toxicity may reoccur within a few days after treatment. [1]

In Australia in 2012 there were about 140 documented cases. [1] This is a decrease by half since 1994 as a result of decreased usage of digoxin. [1] In the United States 2500 cases were reported in 2011 which resulted in 27 deaths. [2] The condition was first described in 1785 by William Withering. [4]

Signs and symptoms

Digoxin toxicity is often divided into acute or chronic toxicity. In both of these toxicity, cardiac effects are of the greatest concern. With an acute ingestion, symptoms such as nausea, vertigo, and vomiting are prominent. On the other hand, nonspecific symptoms are predominant in chronic toxicity. These symptoms include fatigue, malaise, and visual disturbances. [5]

The classic features of digoxin toxicity are nausea, vomiting, abdominal pain, headache, dizziness, confusion, delirium, vision disturbance (blurred or yellow vision). It is also associated with cardiac disturbances including irregular heartbeat, ventricular tachycardia, ventricular fibrillation, sinoatrial block and AV block. [6]

Diagnosis

In individuals with suspected digoxin toxicity, a serum digoxin concentration, serum potassium concentration, creatinine, BUN, and serial electrocardiograms is obtained. [7]

ECG

An ECG showing digoxin toxicity with the classic "scooped out" ST segment DigToxCrop.jpg
An ECG showing digoxin toxicity with the classic "scooped out" ST segment

In digoxin toxicity, the finding of frequent premature ventricular beats (PVCs) is the most common and the earliest dysrhythmia. Sinus bradycardia is also very common. In addition, depressed conduction is a predominant feature of digoxin toxicity. Other ECG changes that suggest digoxin toxicity include bigeminal and trigeminal rhythms, ventricular bigeminy, and bidirectional ventricular tachycardia. [5]

Blood test

The level of digoxin for treatment is typically 0.5-2 ng/mL. [8] Since this is a narrow therapeutic index, digoxin overdose can happen. A serum digoxin concentration of 0.5-0.9 ng/mL among those with heart failure is associated with reduced heart failure deaths and hospitalizations. [9] It is therefore recommended that digoxin concentration be maintained in approximately this range if it is used in heart failure patients.

High amounts of the electrolyte potassium (K+) in the blood (hyperkalemia) is characteristic of digoxin toxicity. [6] Digoxin toxicity increases in individuals who have kidney impairment. This is most often seen in elderly or those with chronic kidney disease or end-stage kidney disease. [10]

Treatment

Digoxin immune Fab used to treat digoxin toxicity Digibind.jpg
Digoxin immune Fab used to treat digoxin toxicity

The primary treatment of digoxin toxicity is digoxin immune fab, which is an antibody made up of anti-digoxin immunoglobulin fragments. This antidote has been shown to be highly effective in treating life-threatening signs of digoxin toxicity such as hyperkalemia, hemodynamic instability, and arrhythmias. [11] Fab dose can be determined by two different methods. First method is based on the amount of digoxin ingested whereas the second method is based on the serum digoxin concentration and the weight of the person. [10]

Other treatment that may be used to treat life-threatening arrhythmias until Fab is acquired are magnesium, phenytoin, and lidocaine. Magnesium suppresses digoxin-induced ventricular arrhythmias while phenytoin and lidocaine suppresses digoxin-induced ventricular automaticity and delay afterdepolarizations without depressing AV conduction. In the case of an abnormally slow heart rate (bradyarrhythmias), Atropine, catecholamines (isoprenaline or salbutamol), and/or temporary cardiac pacing can be used. [8]

Related Research Articles

Cardiac glycoside Class of organic compounds

Cardiac glycosides are a class of organic compounds that increase the output force of the heart and decrease its rate of contractions by inhibiting the cellular sodium-potassium ATPase pump. Their beneficial medical uses are as treatments for congestive heart failure and cardiac arrhythmias; however, their relative toxicity prevents them from being widely used. Most commonly found as secondary metabolites in several plants such as foxglove plants, these compounds nevertheless have a diverse range of biochemical effects regarding cardiac cell function and have also been suggested for use in cancer treatment.

<i>Digitalis</i> Genus of flowering plants in the family Plantaginaceae

Digitalis is a genus of about 20 species of herbaceous perennial plants, shrubs, and biennials, commonly called foxgloves.

Premature ventricular contraction Medical condition

A premature ventricular contraction (PVC) is a common event where the heartbeat is initiated by Purkinje fibers in the ventricles rather than by the sinoatrial node. PVCs may cause no symptoms or may be perceived as a "skipped beat" or felt as palpitations in the chest. PVCs do not usually pose any danger.

Lidocaine Local anesthetic

Lidocaine, also known as lignocaine and sold under the brand name Xylocaine among others, is a local anesthetic of the amino amide type. It is also used to treat ventricular tachycardia. When used for local anaesthesia or in nerve blocks, lidocaine typically begins working within several minutes and lasts for half an hour to three hours. Lidocaine mixtures may also be applied directly to the skin or mucous membranes to numb the area. It is often used mixed with a small amount of adrenaline (epinephrine) to prolong its local effects and to decrease bleeding.

Digoxin Plant-derived medication used in certain heart conditions

Digoxin, sold under the brand name Lanoxin among others, is a medication used to treat various heart conditions. Most frequently it is used for atrial fibrillation, atrial flutter, and heart failure. Digoxin is one of the oldest medications used in the field of cardiology. It works by increasing myocardial contractility, increasing stroke volume and blood pressure, reducing heart rate, and somewhat extending the time frame of the contraction. Digoxin is taken by mouth or by injection into a vein. Digoxin has a half life of approximately 36 hours given at average doses in patients with normal renal function. It is excreted mostly unchanged in the urine.

Digitoxin Chemical compound

Digitoxin is a cardiac glycoside used for the treatment of heart failure and certain kinds of heart arrhythmia. It is a phytosteroid and is similar in structure and effects to digoxin, though the effects are longer-lasting. Unlike digoxin, which is eliminated from the body via the kidneys, it is eliminated via the liver, and so can be used in patients with poor or erratic kidney function. While several controlled trials have shown digoxin to be effective in a proportion of patients treated for heart failure, the evidence base for digitoxin is not as strong, although it is presumed to be similarly effective.

Third-degree atrioventricular block Medical condition

Third-degree atrioventricular block is a medical condition in which the nerve impulse generated in the sinoatrial node in the atrium of the heart can not propagate to the ventricles.

Amiodarone Antiarrhythmic medication used for various types of irregular heartbeats

Amiodarone is an antiarrhythmic medication used to treat and prevent a number of types of cardiac dysrhythmias. This includes ventricular tachycardia (VT), ventricular fibrillation (VF), and wide complex tachycardia, as well as atrial fibrillation and paroxysmal supraventricular tachycardia. Evidence in cardiac arrest, however, is poor. It can be given by mouth, intravenously, or intraosseously. When used by mouth, it can take a few weeks for effects to begin.

Hyperkalemia Medical condition

Hyperkalemia is an elevated level of potassium (K+) in the blood. Normal potassium levels are between 3.5 and 5.0 mmol/L (3.5 and 5.0 mEq/L) with levels above 5.5 mmol/L defined as hyperkalemia. Typically hyperkalemia does not cause symptoms. Occasionally when severe it can cause palpitations, muscle pain, muscle weakness, or numbness. Hyperkalemia can cause an abnormal heart rhythm which can result in cardiac arrest and death.

Electrolyte imbalance Medical condition

Electrolyte imbalance, or water-electrolyte imbalance, is an abnormality in the concentration of electrolytes in the body. Electrolytes play a vital role in maintaining homeostasis in the body. They help to regulate heart and neurological function, fluid balance, oxygen delivery, acid–base balance and much more. Electrolyte imbalances can develop by consuming too little or too much electrolyte as well as excreting too little or too much electrolyte.

Hypokalemia Human disease caused by insufficient potassium

Hypokalemia is a low level of potassium (K+) in the blood serum. Mild low potassium does not typically cause symptoms. Symptoms may include feeling tired, leg cramps, weakness, and constipation. Low potassium also increases the risk of an abnormal heart rhythm, which is often too slow and can cause cardiac arrest.

Cerberin Chemical compound

Cerberin is a type of cardiac glycoside, a steroidal class found in the seeds of the dicotyledonous angiosperm genus Cerbera; including the suicide tree and the sea mango. This class includes digitalis-like agents, channel-blockers that as a group have found historic uses as cardiac treatments, but which at higher doses are extremely toxic; in the case of cerberin, consumption of the C. odollam results in poisoning with presenting nausea, vomiting, and abdominal pain, often leading to death. The natural product has been structurally characterized, its toxicity is clear—it is often used as an intentional human poison in third-world countries, and accidental poisonings with fatalities have resulted from individuals even indirectly consuming the agent—but its potentially therapeutic pharmacologic properties are very poorly described.

Acecainide

Acecainide is an antiarrhythmic drug. Chemically, it is the N-acetylated metabolite of procainamide. It is a Class III antiarrhythmic agent, whereas procainamide is a Class Ia antiarrhythmic drug. It is only partially as active as procainamide; when checking levels, both must be included in the final calculation.

Pulsus bigeminus

Pulsus bigeminus is a cardiovascular phenomenon characterized by groups of two heartbeats close together followed by a longer pause. The second pulse is weaker than the first. Look for a pattern of what appears to be a relatively normal QRS complexes, each followed by a smaller, abnormal one. The smaller beat is palpated as either a missing or an extra beat, and on EKG resembles a PVC. These PVCs appearing every other beat are also called extrasystoles.

Digoxin immune fab

Digoxin immune fab or digoxin-specific antibody is an antidote for overdose of digoxin. It is made from immunoglobulin fragments from sheep that have already been immunized with a digoxin derivative, digoxindicarboxymethoxylamine (DDMA). Its brand names include Digibind (GlaxoSmithKline) and DigiFab.

Lanatoside C

Lanatoside C is a cardiac glycoside, a type of drug that can be used in the treatment of congestive heart failure and cardiac arrhythmia. Lanatoside C can be used orally or by the intravenous route. It is marketed in a number of countries and is also available in generic form. Its main indications are rapid response atrial fibrilation and paroxysmal supraventricular tachycardia, two common types of arrhythmia.

Oleandrin Chemical compound

Oleandrin is a cardiac glycoside found in the poisonous plant oleander. As a main phytochemical of oleander, oleandrin is associated with the toxicity of oleander sap, and has similar properties to digoxin.

Potassium binders are medications that bind potassium ions in the gastrointestinal tract, thereby preventing its intestinal absorption. They consist of polystyrene sulfonate resins attached to a cation and are administered either orally or by retention enema to patients who are at risk of developing hyperkalaemia. Increased serum potassium levels are a condition likely to occur in patients with chronic kidney disease in advanced stages.

Tricyclic antidepressant overdose Medical condition

Tricyclic antidepressant overdose is poisoning caused by excessive medication of the tricyclic antidepressant (TCA) type. Symptoms may include elevated body temperature, blurred vision, dilated pupils, sleepiness, confusion, seizures, rapid heart rate, and cardiac arrest. If symptoms have not occurred within six hours of exposure they are unlikely to occur.

References

  1. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 Pincus, M (February 2016). "Management of digoxin toxicity". Australian Prescriber. 39 (1): 18–20. doi:10.18773/austprescr.2016.006. PMC   4816869 . PMID   27041802.
  2. 1 2 3 4 5 6 7 8 Palatnick, W; Jelic, T (February 2014). "Emergency department management of calcium-channel blocker, beta blocker, and digoxin toxicity". Emergency Medicine Practice. 16 (2): 1–19, quiz 19–20. PMID   24883458. Archived from the original on 2014-05-14.
  3. Gheorghiade, M; van Veldhuisen, DJ; Colucci, WS (30 May 2006). "Contemporary use of digoxin in the management of cardiovascular disorders". Circulation. 113 (21): 2556–64. doi: 10.1161/circulationaha.105.560110 . PMID   16735690.
  4. Feldman, Arthur M. (2008). Heart Failure: Pharmacologic Management. John Wiley & Sons. p. 26. ISBN   9781405172530. Archived from the original on 2017-09-10.
  5. 1 2 Ma, G; Brady, WJ; Pollack, M; Chan, TC (February 2001). "Electrocardiographic manifestations: digitalis toxicity". The Journal of Emergency Medicine . 20 (2): 145–52. doi:10.1016/s0736-4679(00)00312-7. PMID   11207409.
  6. 1 2 Eichhorn, EJ; Gheorghiade, M (2002). "Digoxin". Progress in Cardiovascular Diseases. 44 (4): 251–66. doi:10.1053/pcad.2002.31591. PMID   12007081.
  7. Dugdale, David. "Digitalis toxicity". MedlinePlus. Archived from the original on 1 November 2014. Retrieved 30 October 2014.
  8. 1 2 Bhatia, SJ (July 1986). "Digitalis toxicity--turning over a new leaf?". The Western Journal of Medicine. 145 (1): 74–82. PMC   1306817 . PMID   3529634.
  9. Ahmed, A; Rich, MW; Love, TE; Lloyd-Jones, DM; Aban, IB; Colucci, WS; Adams, KF; Gheorghiade, M (January 2006). "Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial". European Heart Journal. 27 (2): 178–86. doi:10.1093/eurheartj/ehi687. PMC   2685167 . PMID   16339157.
  10. 1 2 Yang, EH; Shah, S; Criley, JM (April 2012). "Digitalis toxicity: a fading but crucial complication to recognize". The American Journal of Medicine. 125 (4): 337–43. doi:10.1016/j.amjmed.2011.09.019. PMID   22444097.
  11. Antman, EM; Wenger, TL; Butler VP, Jr; Haber, E; Smith, TW (June 1990). "Treatment of 150 cases of life-threatening digitalis intoxication with digoxin-specific Fab antibody fragments. Final report of a multicenter study". Circulation. 81 (6): 1744–52. doi: 10.1161/01.cir.81.6.1744 . PMID   2188752.